FDCDDQ
SMMT icon

Federation des caisses Desjardins du Quebec’s Summit Therapeutics SMMT Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$168K Buy
8,881
+268
+3% +$4.33K ﹤0.01% 1566
2025
Q4 		$151K Sell
8,613
-690
-7% -$13K ﹤0.01% 1568
2025
Q3 		$192K Buy
+9,303
New +$226K ﹤0.01% 1484

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's SMMT Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec increased its Summit Therapeutics (SMMT) stake by 3.1% in Q1 2026, buying an estimated $4.33K and bringing the position to 8,881 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #1566.

Federation des caisses Desjardins du Quebec first reported a position in SMMT in Q3 2025 and has held it in 3 quarters since. The position peaked at $192K in Q3 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Federation des caisses Desjardins du Quebec held 8,881 shares of Summit Therapeutics worth $168K as of Q1 2026.
  • Federation des caisses Desjardins du Quebec bought 268 Summit Therapeutics shares in Q1 2026, an estimated $4.33K.
  • Summit Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #1566 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in Summit Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Federation des caisses Desjardins du Quebec's Summit Therapeutics position peaked at $192K in Q3 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.